Effect of Prepregnancy Lymphocyte Active Immunotherapy on Unexplained Recurrent Miscarriage, Pregnancy Success Rate, and Maternal-Infant Outcome.

Junxia Li,Shaojing Zhang,Yan Gu,Baohui Ju,Jianmei Wang,A.Seval Ozgu-Erdinc

doi:10.1155/2021/7878752

Abstract

Objective To evaluate the effect of prepregnancy lymphocyte active immunotherapy on unexplained recurrent miscarriage, pregnancy success rate, and maternal-infant outcome. Methods A total of 124 patients with recurrent miscarriage admitted to our hospital from January 2018 to December 2020 were selected as the research objects and divided into the experimental group and the control group according to the random number table method, with 62 patients in each group. The experimental group was treated with lymphocyte active immunotherapy, and the control group was given conventional treatment. The pregnancy success rate, estrogen indexes, hemorheology indexes, and psychological state of the two groups were compared. Results The experimental group garnered a notably higher pregnancy success rate and a prominently lower miscarriage rate than the control group (P < 0.05). Better results of self-rating anxiety scale (SAS) and self-rating depression scale (SDS) were observed in the experimental group, as compared to the control group (P < 0.05). The experimental group yielded more desirable results in terms of treatment satisfaction, estrogen indexes, and hemorheology indexes in comparison with the control group (P < 0.05). Conclusion The use of lymphocyte active immunotherapy for patients with unexplained recurrent miscarriage can significantly increase the pregnancy success rate, optimize the maternal-infant outcome, drive down the miscarriage rate, and ameliorate the patient's estrogen levels and hemorheology indicators, which is worthy of promotion and application in clinical practice.

Highlights

The spontaneous miscarriage that occurs twice or more in a row is called recurrent miscarriage, and that occurs three times or more in a row is habitual miscarriage
Recurrent miscarriage is considered as a refractory disease in consequence of its rather complicated causes in clinic, among which the miscarriage triggered by immune factors accounts for more than half [12,13,14,15]
It is believed that the genetic antigens from the father during the embryo formation process are treated as foreign invaders, which triggers rejection reactions in the mother; miscarriage indicates the failure of semihomogenous transplantation

Summary

Introduction

The spontaneous miscarriage that occurs twice or more in a row is called recurrent miscarriage, and that occurs three times or more in a row is habitual miscarriage. Relevant studies in recent years have shown that more than half of the causes of unexplained recurrent miscarriage, which has been witnessed an increasing trend recently, are closely related to immune dysfunction, that is, imbalance of pregnancy immune tolerance and abnormal maternal immune regulation. Consensus on the treatment of unexplained recurrent miscarriage has not yet been developed. Despite the safety and effectiveness of lymphocyte active immunotherapy are challenged at times, it is the most common therapy in clinical practice [4,5,6]. This study is to assess the effect of prepregnancy lymphocyte active immunotherapy on unexplained recurrent miscarriage, pregnancy success rate, and maternal-infant outcome.

Methods

Results

Conclusion